Join our daily newsletter At The Bell to receive exclusive market insights
- AdAlta (1AD) has been granted its second patent by the Japanese Patent Office for its lead program, AD-214
- The company says the patent is a “valuable” addition as it will support the expansion of protected claims for AD-214 in Japan which is a major market for fibrosis-related diseases
- The patent will expire on January 9, 2036 and adds to the list of patents received by the company in the US, Singapore and Australia
- Shares in AdAlta last traded at 4 cents on January 10
AdAlta (1AD) has been granted its second patent by the Japanese Patent Office for its lead program, AD-214.
The second patent extends to variations in the i-body scaffold sequence related to AD-214 for treating CXCR4-related diseases or disorders.
This includes the lead indication of idiopathic pulmonary fibrosis as well as cancer, viral infections, inflammatory diseases and immune deficiency disorders, to name a few.
Thus, it extends the range and diversity of sequences analogous to AD-214 that are
protected.
“Japan is the third largest pharmaceutical market in the world and remains important to our partnering and commercialisation strategy,” CEO and Managing Director Tim Oldham said.
“This patent is a valuable, additional piece of intellectual property which enables expansion of protected claims for AD-214 in Japan, a major market for fibrosis-related diseases.”
The patent will expire on January 9, 2036 and adds to the list of patents received by the company in the US, Singapore and Australia.
Shares in AdAlta last traded at 4 cents on January 10.
